Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß...
- Mechanism
- Curator reviewed
Affitope AD01 targets the beta-amyloid protein believed to cause Alzheimer's disease. Beta-amyloid, is present in two forms - as part of a protein (APP) in brain cells and detached in brain fluid. However, only detached beta-amyloid is dangerous, as its deposits (plaques) are a typical feature of Alzheimer's disease. When part of APP, beta-amyloid is essential for healthy brain cell function. If no distinction is made between these two types, an immune response against beta-amyloid can also attack brain cells. Affitope AD01 is able to distinguish between detached beta-amyloid and the beta-amyloid that is part of APP, and directs the immune system to attack only the harmful form of beta-amyloid.
- Primary indication
- Investigated for use/treatment in alzheimer's disease.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Affitope AD01, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account